ଶିଶୁ ମଲ୍ଟିସିଷ୍ଟମ ଇଫ୍ଲାମେଟୋରି ସିଣ୍ଡ୍ରୋମ

Multisystem inflammatory syndrome in children (MIS-C)
Multisystem inflammatory syndrome in children (MIS-C)
; Paediatric multisystem inflammatory syndrome (PMIS/PIMS/PIMS-TS); Multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19; Kawa-COVID-19; Systemic inflammatory syndrome in COVID-19 (SISCoV);
ବିଭାଗ	Pediatrics
ଲକ୍ଷଣ	Fever, abdominal pain, diarrhea, red eyes, rash, vomiting
ଆକ୍ରାନ୍ତ ସମୟ	2–6 weeks after COVID-19
କାରଣ	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
ରୋଗ ନିର୍ଣ୍ଣୟ ପଦ୍ଧତି	Based on symptoms and blood tests after ruling out other causes
ସଠିକ ରୋଗ ନିର୍ଣ୍ଣୟ	Kawasaki disease
ପ୍ରତିକାର	Protecting children from COVID-19
ଔଷଧ	IVIG, steroids, aspirin
ଚିକିତ୍ସା	Supportive care
Prognosis	Long-term outcomes unclear
ପୁନଃପୌନିକ	1 in 3,000 after COVID-19
ମୃତ୍ୟୁ ସାନ୍ଦ୍ରତା	1 to 2%
	[edit on Wikidata]

ଶିଶୁ ମଲ୍ଟିସିଷ୍ଟମ୍ ଇଫ୍ଲାମେଟୋରି ସିଣ୍ଡ୍ରୋମ ( MIS-C ), ଯାହା ଶିଶୁଙ୍କ ପ୍ରଦାହକାରୀ ମଲ୍ଟି ସିଷ୍ଟମ୍ ସିଣ୍ଡ୍ରୋମ ( PIMS ) ଭାବରେ ମଧ୍ୟ ପରିଛିତ, ଏକ ରୋଗ ଯାହା କୋଭିଡ-୧୯ (COVID-19) ସହିତ ଜଡିତ ପିଲାମାନଙ୍କଠାରେ ହୁଏ ।^[୫] ଏହାର ଲକ୍ଷଣ ମଧ୍ୟରେ ଜ୍ୱର ଏବଂ ପେଟ ଯନ୍ତ୍ରଣା, ତରଳ ଝାଡ଼ା, ଲାଲ୍ ଆଖି, ରାସ ବା ବାନ୍ତି ହୋଇପାରେ । ^[୫] ^[୬] ରୋଗ ଜଟିଳ ହେଲେ ହୃତ୍‌ପିଣ୍ଡ, ଫୁସଫୁସ, ବୃକ୍‌କ, ଚର୍ମ କିମ୍ବା ମସ୍ତିଷ୍କ ସମସ୍ୟା ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ। ^[୬]

ଏହା ସାଧାରଣତଃ କୋଭିଡ ଆକ୍ରମଣର ପ୍ରାୟ ୨ରୁ ୬ ସପ୍ତାହ ପରେ ଘଟିଥାଏ ।^[୯] ମୋଟାପଣରେ ଏହା ଅଧିକ ହୁଏ, ପ୍ରଭାବିତ ବ୍ୟକ୍ତିମାନେ ସାଧାରଣତ ଅନ୍ୟଥା ସୁସ୍ଥ ଥାଆନ୍ତି | ^[୯] ଅନ୍ୟାନ୍ୟ ସମ୍ଭାବ୍ୟ କାରଣକୁ ଏଡ଼ାଇବା ପରେ ପ୍ରଦାହର ପରୀକ୍ଷାଗାର ଚିହ୍ନ ଏବଂ ଏକାଧିକ ଶରୀର ପ୍ରଣାଳୀ ପ୍ରଭାବିତ ହୋଇଥିଲେ ରୋଗ ନିର୍ଣ୍ଣୟ କରାଯାଏ। ^[୮] ପୂର୍ବତନ ଏସଏଆରଏସ-କୋଭ-୨ (SARS-୨) ଥିଲେ ସେରୋଲୋଜିକ୍ ପରୀକ୍ଷା ଉପଯୋଗୀ ହୋଇପାରେ ।^[୮] କାୱାସାକି ରୋଗ ଲକ୍ଷଣ ସେହିପରି ଦେଖାଯାଇପାରେ । ^[୯]

କୋଭିଡ଼ ଟିକା ଦେଇ ପିଲାମାନଙ୍କୁ ଏହି ରୋଗରୁ ରକ୍ଷା କରି ହୁଏ ।^[୬] ଚିକିତ୍ସା ମୁଖ୍ୟତଃ ସହାୟକ ଯତ୍ନ ଯେଉଁଥିରେ ଶିରାଭ୍ୟନ୍ତର ତରଳ ପଦାର୍ଥ, ଇନୋଟ୍ରୋପ୍ ଏବଂ ଶ୍ୱାସକ୍ରିୟାର ସୁରକ୍ଷା ଆବଶ୍ୟକ ହୋଇପାରେ । ^[୮] ଗୁରୁତର ଅବସ୍ଥାରେ ଏକ୍ସଟ୍ରାକର୍ପୋରିଅଲ ମେମ୍ବ୍ରେନସ ଅମ୍ଳଜାନ (ECMO) ଆବଶ୍ୟକ ହୋଇପାରେ । ^[୮] ଆଇଭିଆଇଜି (IVIG), ଷ୍ଟିରଏଡ ଏବଂ ଆସ୍ପିରିନ ବ୍ୟବହୃତ ହୋଇପାରେ ।^[୮] ^[୧୦] ପ୍ରଭାବିତଙ୍କ ମଧ୍ୟରୁ ପ୍ରାୟ ୮୦% ଗଭୀର ଚିକିତ୍ସା ଆବଶ୍ୟକ କରନ୍ତି। ^[୯]

କୋଭିଡ ସଂକ୍ରମିତ ୩୦୦୦ ପିଲାଙ୍କ ମଧ୍ୟରୁ ଜଣେ ଏହି ରୋଗରେ ପ୍ରଭାବିତ ହୁଏ ।^[୧୦] ପ୍ରାୟ ୯ ବର୍ଷ ବୟସର ପିଲାମାନେ ସାଧାରଣତଃ ପ୍ରଭାବିତ ହୁଅନ୍ତି ।^[୧୦] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହା କଳା ଏବଂ ହିସପାନିକ ପିଲାମାନଙ୍କଠାରେ ଅଧିକ ଦେଖାଯାଏ। ^[୧୦]ପ୍ରାୟ ୧ରୁ ୨% ପିଲାଙ୍କର ମୃତ୍ୟୁ ଘଟିଥାଏ । ^[୯] ଏହି ଅବସ୍ଥା ପ୍ରଥମେ ଏପ୍ରିଲ୍ ୨୦୨୦ ମସିହାରେ ବର୍ଣ୍ଣନା କରାଯାଇଥିଲା ।^[୧୦] ପ୍ରାପ୍ତ ବୟଷ୍କ କ୍ଷେତ୍ରରେ ଏହି ଭଳି ଦେଖାଯାଉଥିବା ରୋଗକୁ ମଲ୍ଟିସିଷ୍ଟମ୍ ଇଫ୍ଲାମେଟୋରି ସିଣ୍ଡ୍ରୋମ କୁହାଯାଏ ।^[୯]

ଆଧାର

↑ "Rapid risk assessment: Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children" (PDF) (in ଇଂରାଜୀ). European Centre for Disease Prevention and Control. 15 May 2020. Archived from the original on 15 May 2020.
↑ "Case Report Form for suspected cases of multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19". www.who.int (in ଇଂରାଜୀ). World Health Organization. Archived from the original on 24 June 2020.
↑ Pouletty M, Borocco C, Ouldali N, et al. (June 2020). "Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort". Annals of the Rheumatic Diseases. 79 (8): 999–1006. doi:10.1136/annrheumdis-2020-217960. PMC 7299653. PMID 32527868. S2CID 219607184.
↑ Dhar D, Dey T, Samim MM, et al. (2021). "Systemic inflammatory syndrome in COVID-19-SISCoV study: systematic review and meta-analysis". Pediatric Research. doi:10.1038/s41390-021-01545-z. PMC 8128982. PMID 34006982.
↑ ^୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ Ahmed M, Advani S, Moreira A, et al. (September 2020). "Multisystem inflammatory syndrome in children: a systematic review". EClinicalMedicine. 26: 100527. doi:10.1016/j.eclinm.2020.100527. ISSN 2589-5370. PMC 7473262. PMID 32923992. S2CID 221494176.
↑ ^୬.୦ ^୬.୧ ^୬.୨ ^୬.୩ ^୬.୪ "Multisystem Inflammatory Syndrome (MIS)". Centers for Disease Control and Prevention (in ଆମେରିକୀୟ ଇଂରାଜୀ). 11 February 2020. Archived from the original on 13 January 2022. Retrieved 20 January 2022.
↑ Henderson LA, Canna SW, Friedman KG, et al. (July 2020). "American College of Rheumatology clinical guidance for pediatric patients with multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 and hyperinflammation in COVID-19. Version 1". Arthritis & Rheumatology. 72 (11): 1791–1805. doi:10.1002/art.41454. PMC 7405113. PMID 32705809.
↑ ^୮.୦ ^୮.୧ ^୮.୨ ^୮.୩ ^୮.୪ ^୮.୫ ^୮.୬ ^୮.୭ "Multisystem Inflammatory Syndrome (MIS)". Centers for Disease Control and Prevention (in ଆମେରିକୀୟ ଇଂରାଜୀ). 11 February 2020. Archived from the original on 16 December 2021. Retrieved 20 January 2022.
↑ ^୯.୦ ^୯.୧ ^୯.୨ ^୯.୩ ^୯.୪ ^୯.୫ ^୯.୬ ^୯.୭ "Children". COVID-19 Treatment Guidelines (in ଇଂରାଜୀ). Archived from the original on 19 July 2020. Retrieved 20 January 2022.
↑ ^୧୦.୦ ^୧୦.୧ ^୧୦.୨ ^୧୦.୩ ^୧୦.୪ ^୧୦.୫ ^୧୦.୬ ^୧୦.୭ "Ten Things to Know About MIS-C". American College of Cardiology. Archived from the original on 6 January 2022. Retrieved 20 January 2022.

[ECDC-2020-1] "Rapid risk assessment: Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children" (PDF) (in ଇଂରାଜୀ). European Centre for Disease Prevention and Control. 15 May 2020. Archived from the original on 15 May 2020.

[WHO-CRP-2] "Case Report Form for suspected cases of multisystem inflammatory syndrome (MIS) in children and adolescents temporally related to COVID-19". www.who.int (in ଇଂରାଜୀ). World Health Organization. Archived from the original on 24 June 2020.

[Pouletty2020-3] Pouletty M, Borocco C, Ouldali N, et al. (June 2020). "Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort". Annals of the Rheumatic Diseases. 79 (8): 999–1006. doi:10.1136/annrheumdis-2020-217960. PMC 7299653. PMID 32527868. S2CID 219607184.

[Dhar2021-4] Dhar D, Dey T, Samim MM, et al. (2021). "Systemic inflammatory syndrome in COVID-19-SISCoV study: systematic review and meta-analysis". Pediatric Research. doi:10.1038/s41390-021-01545-z. PMC 8128982. PMID 34006982.

[Ahmed2020-5] ୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ Ahmed M, Advani S, Moreira A, et al. (September 2020). "Multisystem inflammatory syndrome in children: a systematic review". EClinicalMedicine. 26: 100527. doi:10.1016/j.eclinm.2020.100527. ISSN 2589-5370. PMC 7473262. PMID 32923992. S2CID 221494176.

[CDC2022Pt-6] ୬.୦ ^୬.୧ ^୬.୨ ^୬.୩ ^୬.୪ "Multisystem Inflammatory Syndrome (MIS)". Centers for Disease Control and Prevention (in ଆମେରିକୀୟ ଇଂରାଜୀ). 11 February 2020. Archived from the original on 13 January 2022. Retrieved 20 January 2022.

[ACR1-7] Henderson LA, Canna SW, Friedman KG, et al. (July 2020). "American College of Rheumatology clinical guidance for pediatric patients with multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 and hyperinflammation in COVID-19. Version 1". Arthritis & Rheumatology. 72 (11): 1791–1805. doi:10.1002/art.41454. PMC 7405113. PMID 32705809.

[CDC2022Pro-8] ୮.୦ ^୮.୧ ^୮.୨ ^୮.୩ ^୮.୪ ^୮.୫ ^୮.୬ ^୮.୭ "Multisystem Inflammatory Syndrome (MIS)". Centers for Disease Control and Prevention (in ଆମେରିକୀୟ ଇଂରାଜୀ). 11 February 2020. Archived from the original on 16 December 2021. Retrieved 20 January 2022.

[NIH2022-9] ୯.୦ ^୯.୧ ^୯.୨ ^୯.୩ ^୯.୪ ^୯.୫ ^୯.୬ ^୯.୭ "Children". COVID-19 Treatment Guidelines (in ଇଂରାଜୀ). Archived from the original on 19 July 2020. Retrieved 20 January 2022.

[ACC2021-10] ୧୦.୦ ^୧୦.୧ ^୧୦.୨ ^୧୦.୩ ^୧୦.୪ ^୧୦.୫ ^୧୦.୬ ^୧୦.୭ "Ten Things to Know About MIS-C". American College of Cardiology. Archived from the original on 6 January 2022. Retrieved 20 January 2022.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]

[୧୦]